US HHS Secretary RFK Jr says FDA is to remove many peptides from category two

This development signals a regulatory shift affecting the use of certain peptides, which may impact the biotech and pharmaceutical sectors significantly.

Newsquawk StaffPublished On the live feed at 2 more headlines followed before this page went public
Newsquawk headlinesUTC

Alphabet (GOOGL) poised for USD 100bln windfall on SpaceX investment

Israeli PM Netanyahu says in talks with Lebanon there are two main objectives, the disarming of Hezbollah and sustainable peace that is achived through strength

US HHS Secretary RFK Jr says FDA is to remove many peptides from category two

BoE Governor Bailey says willingness to fund public debt is a vulnerability

Fed's Bowman (voter) says hope to finalise Basel rulemaking by end of the year; still reviewing liqudity framework

Open the platform and use it. The whole workspace is free to try, with no signup and no card. When you want the headlines arriving live instead of on a delay, Newsquawk Pro is £24.99 for 7 days.

Free. No signup, no card.
Context

The FDA's decision could influence supply chains and market dynamics as firms adapt to these changes, potentially driving stock volatility in affected equities. Additionally, this could signal a more stringent regulatory environment for drug approvals, which may weigh on investor sentiment.

Related headlines

The whole workspace, free to try.

Try it free